I. Chang

发表

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

D. Arnold, S. Muley, P. Vermersch, 2018, The Lancet Neurology.

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing

P. Ho, N. Campbell, I. Chang, 2020, Journal of clinical pharmacology.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

S. Richman, H. Koendgen, P. Ho, 2017, The Lancet Neurology.

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function[S]

D. Rader, S. Reddy, M. Navab, 2011, Journal of Lipid Research.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

D. Centonze, G. Marfia, D. Arnold, 2019, The Lancet Neurology.

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial

M. Elkind, S. Johnston, J. Montaner, 2017, The Lancet Neurology.

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.

Timothy A. Miller, A. Pestronk, P. Andersen, 2020, The New England journal of medicine.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.

Considerations for characterizing the risk of PML in natalizumab-treated patients.

H. Koendgen, P. Ho, I. Chang, 2016, Multiple sclerosis and related disorders.

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

G. Cutter, C. Hotermans, J. Goldberg, 2019, Neurology.

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis

L. Kappos, P. Calabresi, G. Giovannoni, 2022, Multiple sclerosis.

Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial (S7.005)

M. Elkind, J. Montaner, M. Lansberg, 2016 .

Natalizumab Extended Interval Dosing Is Associated with a Reduction in Progressive Multifocal Leukoencephalopathy (PML) Risk in the Touch® Registry

G. Cutter, C. Hotermans, J. Goldberg, 2018 .

The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor

R. Bertz, T. Marbury, T. Eley, 2015, Antiviral therapy.

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

J. Hobart, P. Feys, T. Ziemssen, 2018, CNS Drugs.

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

J. Krystal, C. Correll, J. Renger, 2022, The Lancet.

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects

Y. Yazdanpanah, F. Raffi, R. Bertz, 2013, Journal of acquired immune deficiency syndromes.

Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the TOUCH® Prescribing Program

G. Cutter, C. Hotermans, J. Goldberg, 2019, Revue Neurologique.

071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program

G. Cutter, C. Hotermans, J. Goldberg, 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

Hydralazine dose-response curve analysis

B. Steiger, K. Muir, I. Chang, 1990, Journal of Pharmacokinetics and Biopharmaceutics.

Application of NONMEM to routine bioavailability data

I. Chang, David A. Graves, Ih. Chang, 1990, Journal of Pharmacokinetics and Biopharmaceutics.

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

L. Kappos, M. Trojano, H. Wiendl, 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability

Gary R Cutter, Paul M Matthews, Peter Feys, 2017, Multiple sclerosis.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.